Table 1.
Untreated/Inactive demographics andclinical information.
| Control | Untreated | Inactive | |||
|---|---|---|---|---|---|
| n = 12 | n = 11 | n = 8 | |||
| Demographics | |||||
| Age, mean (sd) | 13.2 (5.3) | 6.8 (3.7) | 11.2 (3.4) | ||
| Female, n (%) | 6 (50.0) | 9 (81.8) | 8 (100.0) | ||
| African American, n (%) | 1 (8.3) | 0 (0.0) | 0 (0.0) | ||
| Asian, n (%) | 0 (0.0) | 1 (9.1) | 0 (0.0) | ||
| Hispanic, n (%) | 2 (16.7) | 1 (9.1) | 1 (12.5) | ||
| White, n (%) | 9 (75.0) | 9 (81.8) | 7 (87.5) | ||
| n | Mean (sd) | n | Mean (sd) | ||
|---|---|---|---|---|---|
| Disease activity | |||||
| DAS Muscle | 9 | 6.1 (3.4) | 8 | 0.2 (0.5) | |
| DAS Skin | 9 | 5.3 (1.8) | 8 | 0.6 (1.4) | |
| DAS Total | 9 | 11.4 (4.2) | 8 | 0.8 (1.6) | |
| Duration untreated disease (mo) | 15.2 (20.6) | 15.4 (24.0) | |||
| CMAS, all ages [max 52] | 10 | 25.5 (16.4) | 6 | 50.5 (2.0) | |
| CMAS, ages < 5.00 [max 46] | 3 | 23.7 (20.0) | |||
| CMAS, ages ≥ 5.00 [max 52] | 7 | 26.3 (16.4) | 6 | 50.5 (2.0) | |
| n | Mean (sd) | n | Mean (sd) | ||
|---|---|---|---|---|---|
| Muscle enzymes | |||||
| AST (SGOT)a | 10 | 81.1 (72.4) | 7 | 25.7 (6.0) | |
| ALT (GPT)b | 9 | 44.3 (32.8) | 7 | 14.0 (5.2) | |
| CPKc | 9 | 988.7 (1646.6) | 8 | 96.6 (20.1) | |
| LDHd | 10 | 409.0 (17.8) | 8 | 247.5 (33.9) | |
| Aldolasee | 11 | 14.0 (10.4) | 6 | 4.6 (1.1) | |
| n (%) | n (%) | ||||
|---|---|---|---|---|---|
| MSA | |||||
| Negative | 4 (36.4) | 2 (25.0) | |||
| Anti-MJ | 1 (9.1) | 1 (12.5) | |||
| Anti-p155/140 | 4 (36.4) | 3 (37.5) | |||
| Anti-Mi2 & Anti-p155/140 | 1 (9.1) | 1 (12.5) | |||
| Otherf | 1 (9.1) | 1 (12.5) | |||
The table shows the relevant demographic and clinical parameters for the control, untreated, and inactive groups. The untreated group is younger than both the control and inactive groups. The untreated group also demonstrated higher disease activity score and muscle enzyme measures than the Inactive group.
sd standard deviation, DAS disease activity score, CMAS childhood myositis assessment scale, MSA myositis-specific antibodies.
aAST (SGOT) reference range: ≥ 2 years, 18–57 IU/L.
bALT (GPT) reference range: ≥ 2 years, 2–30 IU/L.
cCPK reference range: 6 mo–5 years, 81–279 IU/L; 6–9 years, 29–268 IU/L; 10–13 years, 26–268 IU/L; ≥ 14 years, 29–204 IU/L.
dLDH reference range: 2 years, 235–438 IU/L; 3–6 years, 188–403 IU/L; 7–11 years, 188–358 IU/L; ≥ 12 years, 147–355 IU/L.
eAldolase reference range: < 2 years, 3.4–11.8 U/L; 2–17 years, 3.4–8.6 U/L; ≥ 18 years, ≤ 8.1 U/L.
fAnti-MJ+, anti-p155/140 indeterminate, Anti-U5RNP possible.